Under doctor care, this pair may be considered for adults who are healing from injuries or who want extra support for daily wellness
Thus, the values calculated in Table 3 for these precursors should be considered as concentrations that could potentially be achieved rather than absolute concentrations
[3] The European Food Safety Authority (EFSA) sets a more conservative tolerable upper intake level of 250 mg per day from supplements and fortified foods combined
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
Instead, giving details like, "I felt nauseous on Tuesday and Thursday, both around 10 a.m., two days after my injection" gives your doctor useful information to work with
Supernatants were incubated for 4 h at 4 C with 1 g anti-Met rabbit polyclonal antibody (Santa Cruz), then incubated for 12 h at 4 C with 30 l of Dynabeads protein G (Invitrogen)
